Logo image of XOMAO

XOMA ROYALTY CORP - XOMA 8 3/8 PERP (XOMAO) Stock Fundamental Analysis

NASDAQ:XOMAO - US98419J4040

25.4999 USD
-0.01 (-0.03%)
Last: 9/5/2025, 4:30:02 PM
Fundamental Rating

4

XOMAO gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 542 industry peers in the Biotechnology industry. While XOMAO is still in line with the averages on profitability rating, there are concerns on its financial health. XOMAO is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

In the past year XOMAO has reported negative net income.
XOMAO had a negative operating cash flow in the past year.
In multiple years XOMAO reported negative net income over the last 5 years.
The reported operating cash flow has been mixed in the past 5 years: XOMAO reported negative operating cash flow in multiple years.
XOMAO Yearly Net Income VS EBIT VS OCF VS FCFXOMAO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M

1.2 Ratios

With an excellent Return On Assets value of -7.93%, XOMAO belongs to the best of the industry, outperforming 84.87% of the companies in the same industry.
With an excellent Return On Equity value of -19.17%, XOMAO belongs to the best of the industry, outperforming 85.24% of the companies in the same industry.
XOMAO's Return On Invested Capital of 3.73% is amongst the best of the industry. XOMAO outperforms 92.07% of its industry peers.
Industry RankSector Rank
ROA -7.93%
ROE -19.17%
ROIC 3.73%
ROA(3y)-14.85%
ROA(5y)-6.52%
ROE(3y)-31.32%
ROE(5y)-15.58%
ROIC(3y)N/A
ROIC(5y)N/A
XOMAO Yearly ROA, ROE, ROICXOMAO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 400 600 800 1K

1.3 Margins

With an excellent Operating Margin value of 21.23%, XOMAO belongs to the best of the industry, outperforming 95.20% of the companies in the same industry.
XOMAO does not have Profit Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM 21.23%
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
XOMAO Yearly Profit, Operating, Gross MarginsXOMAO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

2

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so XOMAO is destroying value.
XOMAO has more shares outstanding than it did 1 year ago.
The number of shares outstanding for XOMAO has been increased compared to 5 years ago.
XOMAO has a worse debt/assets ratio than last year.
XOMAO Yearly Shares OutstandingXOMAO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
XOMAO Yearly Total Debt VS Total AssetsXOMAO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

XOMAO has an Altman-Z score of -5.49. This is a bad value and indicates that XOMAO is not financially healthy and even has some risk of bankruptcy.
XOMAO's Altman-Z score of -5.49 is on the low side compared to the rest of the industry. XOMAO is outperformed by 62.73% of its industry peers.
A Debt/Equity ratio of 1.11 is on the high side and indicates that XOMAO has dependencies on debt financing.
XOMAO's Debt to Equity ratio of 1.11 is on the low side compared to the rest of the industry. XOMAO is outperformed by 77.31% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.11
Debt/FCF N/A
Altman-Z -5.49
ROIC/WACC0.37
WACC10.13%
XOMAO Yearly LT Debt VS Equity VS FCFXOMAO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

XOMAO has a Current Ratio of 4.88. This indicates that XOMAO is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of XOMAO (4.88) is comparable to the rest of the industry.
A Quick Ratio of 4.88 indicates that XOMAO has no problem at all paying its short term obligations.
XOMAO has a Quick ratio (4.88) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 4.88
Quick Ratio 4.88
XOMAO Yearly Current Assets VS Current LiabilitesXOMAO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

6

3. Growth

3.1 Past

XOMAO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -38.74%.
The Revenue has grown by 168.71% in the past year. This is a very strong growth!
The Revenue has been growing by 9.17% on average over the past years. This is quite good.
EPS 1Y (TTM)-38.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-47.62%
Revenue 1Y (TTM)168.71%
Revenue growth 3Y-9.28%
Revenue growth 5Y9.17%
Sales Q2Q%18.39%

3.2 Future

The Earnings Per Share is expected to grow by 37.32% on average over the next years. This is a very strong growth
XOMAO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 35.53% yearly.
EPS Next Y117.66%
EPS Next 2Y44.5%
EPS Next 3Y37.32%
EPS Next 5YN/A
Revenue Next Year78.53%
Revenue Next 2Y41.78%
Revenue Next 3Y35.53%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
XOMAO Yearly Revenue VS EstimatesXOMAO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M
XOMAO Yearly EPS VS EstimatesXOMAO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -2 -4 -6 -8 -10

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for XOMAO. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 140.71, the valuation of XOMAO can be described as expensive.
Based on the Price/Forward Earnings ratio, XOMAO is valued cheaper than 87.27% of the companies in the same industry.
XOMAO's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 22.69.
Industry RankSector Rank
PE N/A
Fwd PE 140.71
XOMAO Price Earnings VS Forward Price EarningsXOMAO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100

4.2 Price Multiples

XOMAO's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. XOMAO is cheaper than 92.25% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 30.08
XOMAO Per share dataXOMAO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

XOMAO's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
XOMAO's earnings are expected to grow with 37.32% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y44.5%
EPS Next 3Y37.32%

More info and screens

5

5. Dividend

5.1 Amount

With a Yearly Dividend Yield of 8.24%, XOMAO is a good candidate for dividend investing.
XOMAO's Dividend Yield is rather good when compared to the industry average which is at 164.28. XOMAO pays more dividend than 99.63% of the companies in the same industry.
XOMAO's Dividend Yield is rather good when compared to the S&P500 average which is at 2.32.
Industry RankSector Rank
Dividend Yield 8.24%

5.2 History

XOMAO has been paying a dividend for over 5 years, so it has already some track record.
XOMAO has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years3
XOMAO Yearly Dividends per shareXOMAO Yearly Dividends per shareYearly Dividends per share 2021 2022 2023 2024 2025 0.5 1 1.5 2

5.3 Sustainability

XOMAO has negative earnings and hence a negative payout ratio. The dividend may be in danger.
DP-30.88%
EPS Next 2Y44.5%
EPS Next 3Y37.32%
XOMAO Yearly Income VS Free CF VS DividendXOMAO Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M

More info and screens

XOMA ROYALTY CORP - XOMA 8 3/8 PERP

NASDAQ:XOMAO (9/5/2025, 4:30:02 PM)

25.4999

-0.01 (-0.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-13 2025-08-13/bmo
Earnings (Next)11-05 2025-11-05
Inst Owners62.65%
Inst Owner ChangeN/A
Ins Owners1.34%
Ins Owner ChangeN/A
Market Cap308.29M
Analysts82
Price Target51.45 (101.77%)
Short Float %0.01%
Short Ratio0.31
Dividend
Industry RankSector Rank
Dividend Yield 8.24%
Yearly Dividend0.47
Dividend Growth(5Y)N/A
DP-30.88%
Div Incr Years0
Div Non Decr Years3
Ex-Date07-03 2025-07-03 (0.52344)
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)207.59%
Min EPS beat(2)119.7%
Max EPS beat(2)295.48%
EPS beat(4)2
Avg EPS beat(4)28.19%
Min EPS beat(4)-256.98%
Max EPS beat(4)295.48%
EPS beat(8)3
Avg EPS beat(8)57.63%
EPS beat(12)4
Avg EPS beat(12)26.41%
EPS beat(16)5
Avg EPS beat(16)-3.83%
Revenue beat(2)2
Avg Revenue beat(2)76.76%
Min Revenue beat(2)32.7%
Max Revenue beat(2)120.82%
Revenue beat(4)3
Avg Revenue beat(4)39.95%
Min Revenue beat(4)-2.38%
Max Revenue beat(4)120.82%
Revenue beat(8)5
Avg Revenue beat(8)13.46%
Revenue beat(12)7
Avg Revenue beat(12)9.54%
Revenue beat(16)8
Avg Revenue beat(16)-1.84%
PT rev (1m)-19.67%
PT rev (3m)-25.69%
EPS NQ rev (1m)72.73%
EPS NQ rev (3m)74.52%
EPS NY rev (1m)278.33%
EPS NY rev (3m)165.66%
Revenue NQ rev (1m)8.53%
Revenue NQ rev (3m)22%
Revenue NY rev (1m)6.66%
Revenue NY rev (3m)45.88%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 140.71
P/S 6.86
P/FCF N/A
P/OCF N/A
P/B 3.33
P/tB 6.56
EV/EBITDA 30.08
EPS(TTM)-1.54
EYN/A
EPS(NY)0.18
Fwd EY0.71%
FCF(TTM)-1.91
FCFYN/A
OCF(TTM)-0.24
OCFYN/A
SpS3.72
BVpS7.65
TBVpS3.89
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -7.93%
ROE -19.17%
ROCE 4.73%
ROIC 3.73%
ROICexc 6.38%
ROICexgc 10.37%
OM 21.23%
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-14.85%
ROA(5y)-6.52%
ROE(3y)-31.32%
ROE(5y)-15.58%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.2
Health
Industry RankSector Rank
Debt/Equity 1.11
Debt/FCF N/A
Debt/EBITDA 9.33
Cap/Depr 1425.07%
Cap/Sales 44.89%
Interest Coverage 0.78
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.88
Quick Ratio 4.88
Altman-Z -5.49
F-Score5
WACC10.13%
ROIC/WACC0.37
Cap/Depr(3y)7738.51%
Cap/Depr(5y)4653.1%
Cap/Sales(3y)108.05%
Cap/Sales(5y)64.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-38.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-47.62%
EPS Next Y117.66%
EPS Next 2Y44.5%
EPS Next 3Y37.32%
EPS Next 5YN/A
Revenue 1Y (TTM)168.71%
Revenue growth 3Y-9.28%
Revenue growth 5Y9.17%
Sales Q2Q%18.39%
Revenue Next Year78.53%
Revenue Next 2Y41.78%
Revenue Next 3Y35.53%
Revenue Next 5YN/A
EBIT growth 1Y141.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year179.83%
EBIT Next 3Y51.02%
EBIT Next 5YN/A
FCF growth 1Y34.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y85.47%
OCF growth 3YN/A
OCF growth 5YN/A